Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China

MT Newswires Live

Jan 07

Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.

The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.

The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601803050"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601803050\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601803050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601803050","market":"fut","top_or_hot":-1,"title":"Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China","media":"MT Newswires Live","content":"<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.</p><p>The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.</p><p>The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-07 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.</p><p>The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.</p><p>The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601803050","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601803050","pubTimestamp":1767791551,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Livzon Pharmaceutical Group  said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","01513":"丽珠医药","000513":"丽珠集团","BK1191":"制药","BK0188":"融资融券","BK0187":"一线龙头"},"translate_title":"丽珠医药旗下斑块型银屑病药物获中国优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000513":0.9,"01513":0.9},"content_text":"Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}